Developing new antibiotics to treat non-tuberculosis mycobacterial infections


The work with Shionogi and Hsiri serves to develop a new class of antibiotics to treat non-tuberculosis mycobacterial infections, which is a growing problem in Japan and other high income countries. The work, which is taking place at the University of Notre Dame as well as in Osaka, Japan, will involve producing and testing various analogs of imidazo[1,2-a]pyridine-3-carboxamides with the goal of obtaining at least one lead compound for testing in phase 1 clinical trials.

Research Focus

  • Infectious Diseases

    At the EIGH, our researchers work to combat a number of various illnesses, including infectious diseases caused by organisms like bacteria, viruses, fungi, and parasites. These diseases can also be spread from one person to another and may be transmitted from animals to humans. 

  • Molecular Biology and Microbiology

    Researchers at the EIGH use microbiology, which encompasses the study of an entire microorganism, and molecular biology, or the interactivity between molecules within a cell of an organism, to better understand disease and improve global health. 

Who’s Involved

EIGH Faculty

Global Partners

  • Shionogi Pharmaceuticals

University of Notre Dame Partnerships

  • Department of Chemistry and Biochemistry

Additional Information

Media Coverage

Shionogi enters into a license and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics, Inc.